Factor XIII Level at Test Zone Diagnostic Center

Introduction to the Factor XIII Level at Test Zone Diagnostic Center

The Factor XIII Level test is a highly specialized coagulation assay performed to evaluate the activity and concentration of Factor XIII (FXIII), also known as fibrin-stabilizing factor or Laki-Lorand factor. Factor XIII is a critical enzyme in the human coagulation cascade, serving as the final step in the blood clotting process. Unlike other clotting factors that participate in the cascade to generate soluble fibrin, Factor XIII is a transglutaminase that chemically cross-links fibrin monomers, converting a weak, soluble fibrin clot into a highly stable, insoluble physical barrier. This cross-linking process provides the mechanical strength necessary to withstand shear stress from blood flow and protects the clot from premature degradation by the fibrinolytic system (specifically plasmin). Consequently, a deficiency in this factor leads to normal initial clot formation followed by premature clot breakdown, manifesting as delayed bleeding clinical scenarios.

At Test Zone Diagnostic Center, the Factor XIII Level assay is performed using state-of-the-art automated coagulation analyzers and advanced functional methodologies, such as chromogenic activity assays and latex-enhanced immunoturbidimetric assays. This test evaluates the functional integrity of the plasma clotting system, specifically focusing on the cross-linking phase of hemostasis. The clinical importance of measuring Factor XIII levels cannot be overstated; standard screening tests like Prothrombin Time (PT), Activated Partial Thromboplastin Time (aPTT), and Thrombin Time (TT) do not detect Factor XIII deficiency because they only measure the time it takes to form the initial soluble fibrin clot. Therefore, specialized testing at Test Zone Diagnostic Center is essential for diagnosing congenital or acquired Factor XIII deficiencies, investigating unexplained delayed bleeding, assessing recurrent pregnancy loss, and monitoring therapeutic interventions. The diagnostic value of this test lies in its ability to identify a potentially life-threatening bleeding disorder that would otherwise remain completely hidden on routine coagulation panels.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is paramount to ensure the clinical accuracy of the Factor XIII Level test, as pre-analytical variables can significantly impact coagulation assay results. Patients undergoing this test at Test Zone Diagnostic Center should adhere to the following preparation guidelines:

• Medication Review: Patients must inform their prescribing physician and the laboratory staff of all medications, particularly anticoagulants (such as heparin, warfarin, direct oral anticoagulants like apixaban or rivaroxaban), antiplatelet agents, and fibrinolytic therapies, as these can interfere with coagulation assays.
• Fasting Requirements: While strict fasting is generally not required for a Factor XIII assay, a light fast of 2 to 4 hours is recommended to prevent lipemia (excess fat in the blood), which can interfere with the optical detection systems used in automated coagulation analyzers.
• Hydration: Adequate hydration with plain water is highly encouraged to facilitate easier venous access and ensure a smooth blood draw.
• Timing of the Test: If the patient has recently received a blood transfusion, plasma infusion, or cryoprecipitate, the test should ideally be delayed or timed in consultation with a hematologist, as these products contain Factor XIII and will temporarily elevate plasma levels, masking an underlying deficiency.
• Stress and Physical Activity: Patients should avoid strenuous physical exercise and extreme emotional stress immediately prior to the blood draw, as acute physiological stress can transiently alter clotting factor levels.

During the Procedure

The collection of the blood sample for the Factor XIII Level test at Test Zone Diagnostic Center follows strict clinical protocols to prevent in vitro clotting and sample activation:

• Patient Positioning: The patient is comfortably seated or placed in a recumbent position. The phlebotomist identifies the patient using at least two unique identifiers to ensure absolute safety and traceability.
• Venipuncture Site Selection: A suitable vein, typically in the antecubital fossa of the arm, is selected and cleansed thoroughly with an antiseptic solution.
• Sample Collection: Blood is drawn using a sterile, single-use needle. The blood is collected directly into a light blue-top tube containing 3.2% buffered sodium citrate (the standard anticoagulant for coagulation testing). The ratio of blood to anticoagulant (9:1) is critical; the tube must be filled completely to the indicated fill line to prevent dilution errors.
• Gentle Mixing: Immediately after collection, the tube is gently inverted 3 to 4 times to mix the sodium citrate with the blood, preventing micro-clot formation without causing hemolysis (rupture of red blood cells).
• Duration and Experience: The venipuncture process itself takes less than two minutes. Patients may feel a brief, mild pinch as the needle enters the vein, but the procedure is otherwise virtually painless.
• Post-Procedure Care: Direct pressure is applied to the puncture site for several minutes until bleeding stops completely, and a sterile bandage is applied. Because patients with suspected Factor XIII deficiency are prone to delayed bleeding, the phlebotomist will ensure that adequate hemostasis is achieved before the patient leaves the collection area.

When is a Factor XIII Level Performed?

Unexplained Delayed Bleeding

Physicians request a Factor XIII Level test when a patient presents with a history of delayed bleeding following trauma, dental extractions, or surgical procedures. In these cases, the initial injury stops bleeding normally because platelets and soluble fibrin form a temporary plug. However, because the clot lacks the stabilizing cross-links provided by Factor XIII, it breaks down prematurely within 24 to 36 hours, leading to secondary, delayed hemorrhage. Identifying this pattern is a classic clinical indication for ordering this specialized assay.

Recurrent Spontaneous Abortions

Factor XIII plays an indispensable role in maintaining pregnancy by facilitating the anchoring of the placenta to the uterus and supporting cytotrophoblast invasion into the endometrium. Women experiencing recurrent spontaneous abortions or unexplained pregnancy loss are often screened for Factor XIII deficiency. A deficiency in this factor can lead to subchorionic hematomas, placental abruption, and subsequent miscarriage, making the Factor XIII Level test a vital component of a comprehensive recurrent pregnancy loss workup.

Poor or Delayed Wound Healing

In addition to its role in coagulation, Factor XIII is involved in tissue repair and wound healing. It cross-links fibronectin to collagen and fibrin, creating a scaffold that supports the migration of fibroblasts and inflammatory cells into the wound site. Patients presenting with chronic, non-healing wounds or abnormal scar tissue formation, especially when accompanied by a mild bleeding tendency, are candidates for Factor XIII testing to rule out a localized or systemic deficiency.

Umbilical Cord Bleeding in Neonates

Bleeding from the umbilical stump within the first few days of life is a pathognomonic clinical sign of severe congenital Factor XIII deficiency, occurring in up to 80% of affected newborns. When a neonate presents with persistent, unexplained bleeding from the umbilical cord site, pediatricians urgently request a Factor XIII Level test. Early diagnosis is critical to initiate prophylactic plasma or recombinant Factor XIII therapy and prevent devastating complications such as intracranial hemorrhage.

Acquired Bleeding Disorders and Inhibitors

Acquired Factor XIII deficiency can develop later in life due to decreased synthesis, increased consumption, or the development of neutralizing autoantibodies (inhibitors) against Factor XIII. This condition is associated with autoimmune diseases, inflammatory bowel disease, liver failure, certain malignancies, and medications like isoniazid. Physicians order this test when a patient with no prior history of bleeding suddenly develops severe, unexplained bruising, hematomas, or mucosal bleeding with normal routine coagulation profiles.

What Does a Factor XIII Level Detect?

The Factor XIII Level test is highly sensitive and specific for identifying various quantitative and qualitative abnormalities in the Factor XIII protein complex. Specifically, this diagnostic assay can detect:

• Severe congenital Factor XIII deficiency (homozygous state, typically characterized by activity levels below 1-5%).
• Mild to moderate congenital Factor XIII deficiency (heterozygous carriers, often presenting with activity levels between 20% and 60%).
• Acquired Factor XIII deficiency secondary to severe hepatic dysfunction or liver cirrhosis (reduced synthesis of clotting factors).
• Acquired Factor XIII deficiency due to inflammatory bowel disease (Crohn’s disease or ulcerative colitis) resulting from mucosal consumption.
• The presence of specific autoantibodies or inhibitors directed against the Factor XIII-A or Factor XIII-B subunits.
• Consumption of Factor XIII during disseminated intravascular coagulation (DIC), where widespread clotting depletes coagulation factors.
• Factor XIII depletion associated with hyperfibrinolysis, where rapid clot breakdown consumes stabilizing factors.
• Reduced Factor XIII levels in patients undergoing major surgical procedures with massive blood loss and subsequent hemodilution.
• Decreased Factor XIII activity in patients with leukemia or other hematological malignancies.
• Drug-induced Factor XIII deficiency, particularly in patients taking antitubercular medications or certain anticonvulsants.
• Inadequate therapeutic levels in patients receiving prophylactic Factor XIII concentrates or fresh frozen plasma.
• Normal Factor XIII activity, ruling out this specific pathway defect in patients with complex bleeding disorders.
• Elevated Factor XIII levels, which may occasionally be observed in acute phase reactions or chronic inflammatory states.
• Subtle functional defects where the antigen level is normal but the enzymatic activity is significantly impaired.
• The underlying cause of delayed post-operative hemorrhage when all other coagulation factors are within normal limits.
• The etiology of recurrent, unexplained soft tissue hematomas and deep muscle bleeding.
• Potential risk factors for intracranial hemorrhage in pediatric patients presenting with unusual bruising patterns.
• The therapeutic efficacy and recovery rate of Factor XIII replacement therapy post-infusion.
• A physiological explanation for impaired myofibroblast migration and delayed dermal wound closure.
• The biochemical basis of placental insufficiency and recurrent early-stage pregnancy losses.

Turnaround Time and Report Access at Test Zone Diagnostic Center

At Test Zone Diagnostic Center, we understand that timely diagnostic results are crucial for effective clinical decision-making, particularly when dealing with potential bleeding disorders. The Factor XIII Level test is a highly specialized assay that requires meticulous laboratory processing, including double-centrifugation to obtain platelet-poor plasma and precise temperature control to preserve enzyme activity. Typically, the turnaround time for this specialized coagulation test is within 24 to 48 hours from the time of sample collection. Once the analysis is complete, the report undergoes a rigorous multi-level review by our consultant pathologists to ensure absolute accuracy and clinical validity. Patients and their referring physicians can access the diagnostic reports securely online through the Test Zone Diagnostic Center web portal or mobile application. Additionally, automated SMS notifications are sent to patients as soon as their verified reports are ready for download, ensuring a seamless, efficient, and stress-free diagnostic experience.

Factor XIII Level Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Factor XIII Functional Activity	70% to 140% of normal plasma activity	Decreased activity (<70% indicating mild, moderate, or severe deficiency; <5% indicates severe congenital deficiency)
Clot Solubility (Urea/Acid)	Clot remains intact and insoluble for >24 hours	Clot dissolves rapidly (typically within 1 to 4 hours), indicating severe Factor XIII deficiency (usually activity <1-5%)
Factor XIII-A Subunit Antigen	Within established laboratory reference range	Significantly reduced or absent in congenital type II deficiency or acquired autoantibody-mediated depletion
Factor XIII-B Subunit Antigen	Within established laboratory reference range	Reduced in congenital type I deficiency (often associated with reduced but detectable A-subunit levels)
Inhibitor Screen (Mixing Study)	No inhibitor detected; patient plasma corrects normal plasma clot stability	Presence of a neutralizing inhibitor; patient plasma fails to correct or actively inhibits normal plasma clot stability
Fibrinogen Level (Differential)	Normal (200 to 400 mg/dL)	Decreased (hypofibrinogenemia) or absent (afibrinogenemia), which can mimic or complicate Factor XIII deficiency symptoms
Thrombin Time (Differential)	Normal (typically 12 to 15 seconds)	Prolonged Thrombin Time, indicating a fibrinogen defect rather than an isolated Factor XIII deficiency

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Test Zone Diagnostic Center for Factor XIII Level?

• Experienced Healthcare Professionals: Our laboratory is staffed by highly trained hematopathologists and medical technologists specializing in complex coagulation disorders.
• Patient-Focused Care: We prioritize patient comfort and safety, ensuring a gentle and professional blood collection experience.
• Quality Diagnostic Services: Test Zone Diagnostic Center adheres to strict international quality control standards for all hematological and coagulation assays.
• Professional Reporting: Our reports are highly detailed, clinically structured, and reviewed by consultant pathologists to facilitate accurate clinical decisions.
• Modern Diagnostic Approach: We utilize state-of-the-art automated coagulation analyzers that offer superior sensitivity and precision.
• Comfortable Environment: Our diagnostic facilities are designed to provide a clean, welcoming, and stress-free environment for patients of all ages.
• Convenient Location: Easily accessible diagnostic centers located strategically to serve the community efficiently.
• Commitment to Accurate Diagnosis: We employ rigorous pre-analytical and analytical protocols to ensure the absolute reliability of every Factor XIII test result.